KDR and ovarian cancer: Importantly, the combination of olaparib and the pan-VEGFR inhibitor cediranib led to a significantly longer median progression-free survival (PFS,16.5 vs. 8.2 months, hazard ratio of 0.50, p = 0.007) compared to olaparib alone in a randomized Phase II study of relapsed high-grade ovarian cancer patients (Ivy et al, 2016; Liu et al, 2019).